Find Clinical Trial

Phase I dose-escalation study of oral administration of MET Tyrosine Kinase Inhibitor S 49076 in patients with advanced solid tumours


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

Active Substance

S049076

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS049076
Protocol CodeCL1-49076-001
EudraCT Code2011-001127-20
ISRCTN CodeISRCTN00759419


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Quote

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility